Lam S, Palcic B, McLean D, Hung J, Korbelik M, Profio A E
Cancer Control Agency of British Columbia, Vancouver, Canada.
Chest. 1990 Feb;97(2):333-7. doi: 10.1378/chest.97.2.333.
Fluorescence imaging using hematoporphyrin derivative (HpD) or Photofrin II as a tumor marker has been used for localization of early bronchogenic carcinoma. Wider clinical application of HpD or Photofrin II as a cancer imaging agent has been hampered by the potentially serious and prolonged skin photosensitivity. Using a sensitive fluorescence bronchoscope system with a ratio fluorometer probe, carcinoma in situ was detected in four patients with low dose Photofrin II (0.25 mg/kg) with no apparent skin phototoxicity to 30 J/cm2 visible light on skin photosensitivity test.
使用血卟啉衍生物（HpD）或光敏素II作为肿瘤标志物的荧光成像已用于早期支气管癌的定位。HpD或光敏素II作为癌症成像剂在临床上更广泛的应用受到潜在严重且持久的皮肤光敏性的阻碍。使用带有比率荧光计探头的灵敏荧光支气管镜系统，在4例接受低剂量光敏素II（0.25mg/kg）的患者中检测到原位癌，在皮肤光敏性试验中对30J/cm2可见光没有明显的皮肤光毒性。
